JDB153

DRUG2 trials

Sponsors

West China Hospital

Conditions

Refractory Hepatocellular CarcinomaRefractory Pancreatic AdenocarcinomaRefractory Pancreatic Ductal Adenocarcinoma

Phase 1

JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure

Not yet recruitingNCT07075419

West China HospitalRefractory Hepatocellular Carcinoma

Start: 2025-08-01End: 2027-08-01Target: 10Updated: 2025-07-20

JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure

Not yet recruitingNCT07175389

West China HospitalRefractory Pancreatic Adenocarcinoma, Refractory Pancreatic Ductal Adenocarcinoma

Start: 2025-10-01End: 2027-10-01Target: 10Updated: 2025-09-16